Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data

• मुख्य लेखकों: Svetlana Garafola (लेखक), Elizabeth Shiferaw (लेखक), Vikram Dev (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Adis, Springer Healthcare, 2023-06-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract Background Brexanolone is currently the only medication approved by the US FDA for the treatment of postpartum depression (PPD) in patients ≥15 years. Brexanolone is available commercially only through a restricted program (ZULRESSO® Risk Evaluation and Mitigation Strategy; REMS) due to ris...